| 项目编号 |
PRJCA021756 |
| 项目标题 |
Precision Induction Therapy for Inoperable NSCLC in Stage III Disease: A Phase II Umbrella Clinical Trial |
| 涉及领域 |
Medical |
| 数据类型 |
Exome
Transcriptome or Gene expression
|
| 物种名称 |
Homo sapiens
|
| 描述信息 |
The objective is to assess the efficacy and safety of precision induction therapies in patients with unresectable stage III NSCLC selected based on tumor PD-L1 expression. Patients were stratified into groups receiving Sintilimab monotherapy, Sintilimab plus IBI305, or Sintilimab combined with chemotherapy. Multi-disciplinary team (MDT) to discuss whether surgery was performed 3-4 weeks after last dose of therapy. Surgery was performed 4-6 weeks after last dose of induction therapy. RNA-seq and WES were performed at baseline, and the tumor samples were also collected for RNA-seq after surgery. Based on bioinformatics analysis, we want to find better biomarker to stratified patients and explore optimized regimens for unresectable stage III NSCLC. |
| 样品范围 |
Multiisolate |
| 发布日期 |
2025-01-26 |
| 项目资金来源 |
| 机构 |
项目类型 |
授权项目ID |
授权项目名称 |
| Shanghai Hospital Development Center
|
|
SHDC2020CR2020B
|
|
|
|
| 项目相关网站链接 |
|
| 提交者 |
Peng
Zhang (zhangpeng1121@tongji.edu.cn)
|
| 提交单位 |
Shanghai Pulmonary Hospital Tongji University |
| 提交日期 |
2023-12-04 |
